Silence Therapeutics signs collaboration with miRagen Therapeutics to evaluate delivery of novel microRNA-based therapeutics
Silence Therapeutics plc announced that it has signed an agreement with miRagen Therapeutics, Inc. to assess the delivery potential of Silence’s proprietary DBTC delivery system with miRagen’s novel microRNA- (miRNA-) based therapeutics.
Under the terms of the agreement, miRagen will provide Silence with specific miRNA sequences, which Silence will formulate with its proprietary DBTC delivery system in order to develop multiple candidate drugs. MiRagen will undertake in vitro and in vivo studies of the candidate drugs developed under the agreement and select lead candidates for further evaluation. Financial terms of the collaboration are not disclosed.
DBTC is a proprietary RNAi delivery system developed by Silence. It is a novel lipid-based formulation that functionally delivers short interfering RNA (siRNA) to liver endothelial cells, hepatocytes and other liver cell types with high efficiency.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Mice regain ability to extend telomeres suggesting potential for dyskeratosis congenita therapy
Greener molecular intermediates may aid drug design

From the road to the plate: lettuce takes up toxic additives from tyre wear - Chemicals from tyre wear could get into our vegetables via sewage sludge and waste water
Merck Announces Future Insight Prize for Groundbreaking Scientific Work - Prize money up to 1 million Euro
David Irby and Richard Reznick are awarded prize in medical education research

Hemp helps to heal - International research team clarifies mode of action of cannabinoids in inflammation
PerkinElmer appoints President & Chief Operating Officer
One molecule, many more insulin-producing cells to treat diabetes, says Pitt team
Aquapharm appoints Dr Simon Best OBE FRSE as new CEO - Current CEO and founder, Andrew Mearns Spragg, to take position as CTO
Diacylglycerol_lipase
Autophagy triggers autoimmune disease
